Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
The Center for Rheumatology and Bone Research
mi
from
Wheaton, MD
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
The Center for Rheumatology and Bone Research
mi
from
Wheaton, MD
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Adriana Pop-Moody MD - Clinic PA
mi
from
Corpus Christi, TX
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Adriana Pop-Moody MD - Clinic PA
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Drug Shipment/Storage: Investigational Drug Services
mi
from
Salt Lake City, UT
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Drug Shipment/Storage: Investigational Drug Services
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Royal Prince Alfred Hospital, Rheumatology Department
mi
from
Camperdown,
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Royal Prince Alfred Hospital, Rheumatology Department
mi
from
Camperdown,
Click here to add this to my saved trials
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated:  4/15/2016
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor
Status: Enrolling
Updated: 4/15/2016
Arizona Arthritis & Rheumatology Associates, PC
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Bakersfield, CA
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Burbank, CA
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
La Jolla, CA
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Tampa, FL
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Tampa, FL
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Boston, MA
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Omaha, NE
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Henderson, NV
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
East Windsor, NJ
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
East Windsor, NJ
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Portland, OR
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  5/4/2016
Site Reference ID/Investigator# 118075
mi
from
Carlton,
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
A Phase 3, Multicenter, Double-Blind, Randomized,Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 5/4/2016
Site Reference ID/Investigator# 118075
mi
from
Carlton,
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Sacramento, CA
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative site
mi
from
Aurora, CO
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative site
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Trumbull, CT
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Trumbull, CT
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Rockville, MD
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Rockville, MD
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Andover, MA
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Andover, MA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative site
mi
from
Boston, MA
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Troy, MI
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Troy, MI
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
East Windsor, NJ
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
East Windsor, NJ
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis
mi
from
New York, NY
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis
mi
from
New York, NY
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Winston-Salem, NC
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Gahanna, OH
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Gahanna, OH
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Hershey, PA
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Arlington, TX
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
Novartis Investigative Site
mi
from
Salt Lake City, UT
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated:  5/4/2016
201, Novartis Investigational Site
mi
from
West Jordan, UT
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis
Status: Enrolling
Updated: 5/4/2016
201, Novartis Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
Pediatric Atopic Dermatitis (AD) Internet Survey
Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis
Status: Enrolling
Updated:  5/5/2016
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Pediatric Atopic Dermatitis (AD) Internet Survey
Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis
Status: Enrolling
Updated: 5/5/2016
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Comparative Analysis of Small and Large Plaque Psoriasis
Comparative Analysis of Small and Large Plaque Psoriasis
Status: Enrolling
Updated:  5/5/2016
Rockefeller University
mi
from
New York, NY
Comparative Analysis of Small and Large Plaque Psoriasis
Comparative Analysis of Small and Large Plaque Psoriasis
Status: Enrolling
Updated: 5/5/2016
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Arthritis Asso & Osteo Ctr Of Colorado Springs
mi
from
Colorado Springs, CO
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Arthritis Asso & Osteo Ctr Of Colorado Springs
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Joao Nascimento, MD
mi
from
Bridgeport, CT
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Joao Nascimento, MD
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
New England Research Associates, Llc
mi
from
Trumbull, CT
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
New England Research Associates, Llc
mi
from
Trumbull, CT
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Klein & Associates MD, PA.
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Tufts Medical Center
mi
from
Boston, MA
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
St. Paul Rheumatology, PA
mi
from
Eagan, MN
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Paramount Medical Research & Consulting, Llc
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
East Penn Rheumatology Associates, P.C.
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated:  6/8/2016
Clinical Research Center of Reading, LLP
mi
from
Wyomissing, PA
Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
Status: Enrolling
Updated: 6/8/2016
Clinical Research Center of Reading, LLP
mi
from
Wyomissing, PA
Click here to add this to my saved trials